Keith McGahan Net Worth

The estimated Net Worth of Keith M Mc Gahan is at least $3.82 millió dollars as of 14 March 2023. Mr. Gahan owns over 42,930 units of Spectrum Pharmaceuticals stock worth over $195,005 and over the last 6 years he sold SPPI stock worth over $616,151. In addition, he makes $3,008,640 as Senior Vice President, Chief Legal Officer és Corporate Secretary at Spectrum Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. McGahan SPPI stock SEC Form 4 insiders trading

Keith has made over 27 trades of the Spectrum Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 42,930 units of SPPI stock worth $34,344 on 14 March 2023.

The largest trade he's ever made was selling 67,152 units of Spectrum Pharmaceuticals stock on 30 January 2023 worth over $39,620. On average, Keith trades about 9,605 units every 51 days since 2018. As of 14 March 2023 he still owns at least 189,325 units of Spectrum Pharmaceuticals stock.

You can see the complete history of Mr. Gahan stock trades at the bottom of the page.

Keith McGahan biography

Keith M. McGahan serves as Senior Vice President, Chief Legal Officer, Corporate Secretary of the Company. Mr. McGahan has served as our Chief Legal Officer since June 2018, as Corporate Secretary since February 2018 and as Executive Vice President since June 2019. From August 2016 to June 2018, he served as Vice President, Chief Compliance Officer and Assistant General Counsel. He brings to Spectrum more than 16 years of diverse experience in the healthcare and pharmaceutical industry. From 2015 through August 2016, Mr. McGahan served an Executive Director and Assistant General Counsel of Avanir Pharmaceuticals Inc., a pharmaceutical company focusing on research and development of cutting-edge treatments and therapies for central nervous system disorders, where he led a team in developing a comprehensive audit and monitoring program and in updating the privacy program, as well as served as legal advisor on all compliance related matters. From 2012 through 2015, he served as Director, Healthcare Compliance of Johnson & Johnson, a multinational medical devices, pharmaceutical and consumer packaged goods company, where he was responsible for executing the global compliance program. Prior to that, from 2007 through 2011, Mr. McGahan served as General Counsel and Chief Compliance Officer of the Naval Hospital at Camp Pendleton.

What is the salary of Keith McGahan?

As the Senior Vice President, Chief Legal Officer és Corporate Secretary of Spectrum Pharmaceuticals, the total compensation of Keith McGahan at Spectrum Pharmaceuticals is $3,008,640. There are 3 executives at Spectrum Pharmaceuticals getting paid more, with Joseph Turgeon having the highest compensation of $5,697,230.

How old is Keith McGahan?

Keith McGahan is 44, he's been the Senior Vice President, Chief Legal Officer és Corporate Secretary of Spectrum Pharmaceuticals since 2018. There are 13 older and no younger executives at Spectrum Pharmaceuticals. The oldest executive at Spectrum Pharmaceuticals, Inc. is Dolatrai Vyas, 76, who is the Independent Director.

What's Keith McGahan's mailing address?

Keith's mailing address filed with the SEC is 2 ATLANTIC AVENUE, , BOSTON, MA, 02110.

Insiders trading at Spectrum Pharmaceuticals

Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen és Thomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.

What does Spectrum Pharmaceuticals do?

spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

Complete history of Mr. Gahan stock trades at Spectrum Pharmaceuticals

Spectrum Pharmaceuticals executives and stock owners

Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include:

• Joseph Turgeon,
  President, Chief Executive Officer, Director
• Thomas Riga,
  Chief Operating Officer, Chief Commercial Officer, Executive Vice President
• Kurt Gustafson,
  Chief Financial Officer, Executive Vice President
• Keith McGahan,
  Senior Vice President, Chief Legal Officer, Corporate Secretary
• Francois Lebel,
  Executive Vice President, Chief Medical Officer
• Thomas J. Riga,
  Pres, CEO & Director
• Kurt A. Gustafson,
  Exec. VP & CFO
• Dr. Francois J. Lebel FRCPC, M.D.,
  Exec. VP & Chief Medical Officer
• Keith M. McGahan J.D., L.L.M.,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• William Ashton,
  Independent Chairman of the Board
• Bernice Welles,
  Independent Director
• Jeffrey Vacirca,
  Independent Director
• Dolatrai Vyas,
  Independent Director
• Elizabeth Czerepak,
  Independent Director
• Seth Fischer,
  Independent Director
• Lyndah Dreiling,
  Senior Vice President, Clinical Development
• Dr. Lyndah K. Dreiling M.B.A., M.D.,
  Sr. VP of Clinical Devel.
• Lisa A. Croissant,
  VP of Sales
• Alberto Dejesus,
  VP of Marketing
• Bimal R. Shah,
  VP of Corp. & Bus. Devel.
• Anthony E Iii Maida,
  Director
• Raymond W Cohen,
  Director
• Stuart Mitchell Krassner,
  Director
• Gilles Gagnon,
  Director
• Luigi Md Lenaz,
  President, Oncology Division
• Juhyun Lim,
  Director
• Jeff L Vacirca,
  Director
• Ann C Phd Kessler,
  Director
• Armin M Kessler,
  Director
• Lee F Md Ph D Allen,
  Chief Medical Officer
• Joseph Kenneth Keller,
  EVP & Chief Operating Officer
• Carol Phd Ocleireacain,
  Director
• Paul H Phd Silverman,
  Director
• Shyam K Kumaria,
  Vice President Finance
• Mark J Glasky,
  Director
• Krishan K Arora,
  Director
• Eric L Phd Nelson,
  Director
• John L Mcmanus,
  VP,Finance, Strategic Planning
• Rajesh C Md Shrotriya,
  Ch, Pres. and Chief Exec. Off.
• Julius A Vida,
  Director
• Dilip J Md Phd Mehta,
  Director
• Richard Fulmer,
  Director
• James Shields,
  Chief Commercial Officer
• Brett L Scott,
  Acting Chief Financial Officer
• Anton Gueth,
  Director
• Mitchell P. Cybulski,
  Director
• George F Tidmarsh,
  CSO AND HEAD OF R&D OPERATIONS
• Nora Brennan,
  See Remarks